Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine.
Frovatriptan is a 5-HT(1B/1D) receptor agonist that belongs to the triptan therapeutic class. Relative to other triptans, frovatriptan has a long half-life (26 h) and a low incidence of migraine recurrence (17%). Frovatriptan is indicated for the acute treatment of migraine with or without aura, and has a relatively good safety and tolerability profile. Recent studies have also shown that a 6-day regimen of frovatriptan scheduled during the perimenstrual period significantly reduced the incidence and severity of menstrual migraine (MM; attacks that regularly start day -2 to +3 relative to menses). Prevention may be important because MM attacks have been characterized as being of longer duration, more severe and more refractory to treatment than non-MM attacks.
Elkind
Arthur H
AH
Elkind Headache Center, 12 North Seventh Avenue, Mount Vernon, NY 10550, USA. arthur.elkind@verizon.net
MacGregor
E Anne
EA
D002227:Carbazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008599:Menstruation Disturbances / Q000150:complications / Q000188:drug therapy*; D008881:Migraine Disorders / Q000150:complications / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D014363:Tryptamines / Q000009:adverse effects / Q000627:therapeutic use*
D002227:Carbazoles; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C108128:frovatriptan